{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:23Z","timestamp":1785466703631,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41372-026-02594-0","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:59:45Z","timestamp":1771840785000},"page":"1123-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A therapeutic revolution: CFTR modulators in cystic fibrosis and their impacts on pregnant women and the fetus"],"prefix":"10.1038","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5005-796X","authenticated-orcid":false,"given":"Marie","family":"Denef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-7038","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Chantraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2594_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12016-008-8077-y","volume":"35","author":"CL Ren","year":"2008","unstructured":"Ren CL. Cystic fibrosis: evolution from a fatal disease of infancy with a clear phenotype to a chronic disease of adulthood with diverse manifestations. Clin Rev Allergy Immunol. 2008;35:97\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2594_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arcped.2022.11.019","volume":"30","author":"P Foucaud","year":"2023","unstructured":"Foucaud P, Mercier JC. CFTR pharmacological modulators: a great advance in cystic fibrosis management. Arch P\u00e9diatrie. janv. 2023;30:1\u20139.","journal-title":"Arch P\u00e9diatrie. janv"},{"key":"2594_CR3","unstructured":"Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2023;88."},{"key":"2594_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK, Volkova N, Ahluwalia N, Sahota G, Xuan F, Chin A, et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J Cyst Fibros. 2023;22:730\u20137.","journal-title":"J Cyst Fibros"},{"key":"2594_CR5","unstructured":"Registre_francais_mucoviscidose_bilan2022.pdf. 2025. Disponible sur: https:\/\/www.vaincrelamuco.org\/sites\/default\/files\/registre_francais_mucoviscidose_bilan2022.pdf."},{"key":"2594_CR6","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann H, Ratjen F. Cystic fibrosis. N Engl J Med. 2023;389:1693\u2013707.","journal-title":"N Engl J Med"},{"key":"2594_CR7","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.3390\/cells10112844","volume":"10","author":"LS Hanssens","year":"2021","unstructured":"Hanssens LS, Duchateau J, Casimir GJ. CFTR protein: not just a chloride channel? Cells. 2021;10:2844.","journal-title":"Cells"},{"key":"2594_CR8","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW. Cystic fibrosis: a review. JAMA. 2023;329:1859.","journal-title":"JAMA"},{"key":"2594_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.arbres.2013.07.013","volume":"50","author":"E Quintana-Gallego","year":"2014","unstructured":"Quintana-Gallego E, Delgado-Pecell\u00edn I, Calero Acu\u00f1a C. CFTR protein repair therapy in cystic fibrosis. Arch Bronconeumol. 2014;50:146\u201350.","journal-title":"Arch Bronconeumol"},{"key":"2594_CR10","doi-asserted-by":"crossref","unstructured":"Mar\u00eda Del Carmen L\u00f3pez C. The history of cystic fibrosis. Open J Pediatr Child Health. 2019;4:001\u20136.","DOI":"10.17352\/ojpch.000015"},{"key":"2594_CR11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/JEP.S255377","volume":"13","author":"MC Pinto","year":"2021","unstructured":"Pinto MC, Silva IAL, Figueira MF, Amaral MD, Lopes-Pacheco M. Pharmacological modulation of ion channels for the treatment of cystic fibrosis. J Exp Pharmacol. 2021;13:693\u2013723.","journal-title":"J Exp Pharmacol"},{"key":"2594_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, D\u0159ev\u00ednek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663\u201372.","journal-title":"N Engl J Med"},{"key":"2594_CR13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"2594_CR14","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet Lond Engl. 2019;394:1940\u20138.","journal-title":"Lancet Lond Engl"},{"key":"2594_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","volume":"13","author":"C Keating","year":"2025","unstructured":"Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, et al. Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20\u2013121-102 and VX20\u2013121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025;13:256\u201371.","journal-title":"Lancet Respir Med"},{"key":"2594_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","volume":"64","author":"FA Elzinga","year":"2025","unstructured":"Elzinga FA, Malik PRV, Akkerman OW, Rottier BL, van der Vaart H, Touw DJ, et al. Pharmacokinetics of ivacaftor, tezacaftor, elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review. Clin Pharmacokinet. 2025;64:999\u20131046.","journal-title":"Clin Pharmacokinet"},{"key":"2594_CR17","doi-asserted-by":"publisher","first-page":"175346662513231","DOI":"10.1177\/17534666251323194","volume":"19","author":"V Terlizzi","year":"2025","unstructured":"Terlizzi V, Lopes-Pacheco M. Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor. Ther Adv Respir Dis. 2025;19:17534666251323194.","journal-title":"Ther Adv Respir Dis"},{"key":"2594_CR18","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jcf.2025.08.008","volume":"24","author":"C H\u00f8jte","year":"2025","unstructured":"H\u00f8jte C, Olsen MF, Faurholt-Jepsen D, J\u00f8rgensen MH, Pressler T, Leo-Hansen C, et al. Severe hepatotoxicity is uncommon following the introduction of elexacaftor\/tezacaftor\/ivacaftor: a real-world two-years follow-up study of the Danish cystic fibrosis cohort. J Cyst Fibros. 2025;24:998\u20131005.","journal-title":"J Cyst Fibros"},{"key":"2594_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00404-023-07153-y","volume":"308","author":"V Dacc\u00f2","year":"2023","unstructured":"Dacc\u00f2 V, Alicandro G, Trespidi L, Gramegna A, Blasi FA. Unplanned pregnancies following the introduction of elexacaftor\/tezacaftor\/ivacaftor therapy in women with cystic fibrosis. Arch Gynecol Obstet. 2023;308:1657\u20139.","journal-title":"Arch Gynecol Obstet"},{"key":"2594_CR20","first-page":"438","volume":"16","author":"B Siegel","year":"1960","unstructured":"Siegel B, Siegel S. Pregnancy and delivery in a patient with cystic fibrosis of the pancreas: report of a case. Obstet Gynecol. 1960;16:438.","journal-title":"Obstet Gynecol"},{"key":"2594_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0140-6736(80)90183-X","volume":"316","author":"F Cohen Lawrence","year":"1980","unstructured":"Cohen Lawrence F, Di Sant\u2019Agnese Paul A, Friedlander J. Cystic fibrosis and pregnancy. Lancet. 1980;316:842\u20134.","journal-title":"Lancet"},{"key":"2594_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/bmj.311.7009.822","volume":"311","author":"FP Edenborough","year":"1995","unstructured":"Edenborough FP, Stableforth DE, Mackenzie WE. Pregnancy in women with cystic fibrosis. BMJ. 1995;311:822\u20133.","journal-title":"BMJ"},{"key":"2594_CR23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1034\/j.1600-0412.2002.810803.x","volume":"81","author":"I \u00d8Degaard","year":"2002","unstructured":"\u00d8Degaard I, Stray-Pedersen B, Hallberg K, Haanaes OC, Storr\u00f8sten OT, Johannesson M. Maternal and fetal morbidity in pregnancies of Norwegian and Swedish women with cystic fibrosis. Acta Obstet Gynecol Scand. 2002;81:698\u2013705.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2594_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1471-0528.2002.01511.x","volume":"109","author":"D Gillet","year":"2002","unstructured":"Gillet D, de Braekeleer M, Bellis G, Durieu I. French Cystic Fibrosis Registry. Cystic fibrosis and pregnancy. Report from French data (1980-1999). BJOG Int J Obstet Gynaecol. 2002;109:912\u20138.","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"2594_CR25","doi-asserted-by":"publisher","first-page":"98.e1","DOI":"10.1016\/j.ajog.2014.07.018","volume":"212","author":"EM Patel","year":"2015","unstructured":"Patel EM, Swamy GK, Heine RP, Kuller JA, James AH, Grotegut CA. Medical and obstetric complications among pregnant women with cystic fibrosis. Am J Obstet Gynecol. 2015;212:98.e1\u201398.e9.","journal-title":"Am J Obstet Gynecol"},{"key":"2594_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejogrb.2024.06.045","volume":"300","author":"S Amar","year":"2024","unstructured":"Amar S, Badeghiesh A, Baghlaf H, Dahan MH. Obstetric and neonatal outcomes among pregnant patients with cystic fibrosis. Eur J Obstet Gynecol Reprod Biol. 2024;300:219\u201323.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2594_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/AOG.0000000000004959","volume":"140","author":"CN Schmidt","year":"2022","unstructured":"Schmidt CN, Friedman AM, DiMango EA, Linder AH, Sobhani NC, D\u2019Alton ME, et al. Trends in and outcomes of deliveries complicated by cystic fibrosis. Obstet Gynecol. 2022;140:861.","journal-title":"Obstet Gynecol"},{"key":"2594_CR28","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1378\/chest.124.4.1460","volume":"124","author":"CH Goss","year":"2003","unstructured":"Goss CH, Rubenfeld GD, Otto K, Aitken ML. The effect of pregnancy on survival in women with cystic fibrosis. Chest. 2003;124:1460\u20138.","journal-title":"Chest"},{"key":"2594_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1378\/chest.118.1.85","volume":"118","author":"M Gilljam","year":"2000","unstructured":"Gilljam M, Antoniou M, Shin J, Dupuis A, Corey M, Tullis DE. Pregnancy in cystic fibrosis. Fetal and maternal outcome. Chest. 2000;118:85\u201391.","journal-title":"Chest"},{"key":"2594_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1378\/chest.129.3.706","volume":"129","author":"AH McMullen","year":"2006","unstructured":"McMullen AH, Pasta DJ, Frederick PD, Konstan MW, Morgan WJ, Schechter MS, et al. Impact of pregnancy on women with cystic fibrosis. Chest. 2006;129:706\u201311.","journal-title":"Chest"},{"key":"2594_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcf.2013.08.004","volume":"13","author":"M Ahluwalia","year":"2014","unstructured":"Ahluwalia M, Hoag JB, Hadeh A, Ferrin M, Hadjiliadis D. Cystic fibrosis and pregnancy in the modern era: a case control study. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2014;13:69\u201373.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jcf.2019.06.003","volume":"19","author":"Q Reynaud","year":"2020","unstructured":"Reynaud Q, Rousset Jablonski C, Poupon-Bourdy S, Denis A, Rabilloud M, Lemonnier L, et al. Pregnancy outcome in women with cystic fibrosis and poor pulmonary function. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2020;19:80\u20133.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcf.2020.09.002","volume":"20","author":"M Cohen-Cymberknoh","year":"2021","unstructured":"Cohen-Cymberknoh M, Gindi Reiss B, Reiter J, Lechtzin N, Melo J, P\u00e9rez G, et al. Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20:388\u201394.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","volume":"21","author":"R Jain","year":"2022","unstructured":"Jain R, Kazmerski TM, Zuckerwise LC, West NE, Montemayor K, Aitken ML, et al. Pregnancy in cystic fibrosis: review of the literature and expert recommendations. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21:387\u201395.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","volume":"167","author":"R Jain","year":"2025","unstructured":"Jain R, Peng G, Lee M, Keller A, Cosmich S, Reddy S, et al. Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy. Chest. 2025;167:348\u201361.","journal-title":"Chest"},{"key":"2594_CR36","first-page":"101776","volume":"40","author":"Z Balmpouzis","year":"2022","unstructured":"Balmpouzis Z, Faure van Rossum A, Baud D, Panchaud A, Mitropoulou G, Mazza Stalder J, et al. Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor. Respir Med Case Rep. 2022;40:101776.","journal-title":"Respir Med Case Rep"},{"key":"2594_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.clinthera.2023.01.016","volume":"45","author":"JL Taylor-Cousar","year":"2023","unstructured":"Taylor-Cousar JL, Shteinberg M, Cohen-Cymberknoh M, Jain R. The impact of highly effective cystic fibrosis transmembrane conductance regulator modulators on the health of female subjects with cystic fibrosis. Clin Ther. 2023;45:278\u201389.","journal-title":"Clin Ther"},{"key":"2594_CR38","doi-asserted-by":"publisher","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","volume":"9","author":"R Jain","year":"2022","unstructured":"Jain R, Magaret A, Vu PT, VanDalfsen JM, Keller A, Wilson A, et al. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022;9:e001289.","journal-title":"BMJ Open Respir Res"},{"key":"2594_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","volume":"17","author":"A Trimble","year":"2018","unstructured":"Trimble A, McKinzie C, Terrell M, Stringer E, Esther CR. Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2018;17:779\u201382.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR40","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","volume":"21","author":"B Collins","year":"2022","unstructured":"Collins B, Fortner C, Cotey A, Esther CRJ, Trimble A. Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21:725\u20137.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR41","unstructured":"FDA. 212273s004lbl.pdf. 2025. Disponible sur: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"key":"2594_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1165\/rcmb.2022-0175LE","volume":"67","author":"M Lhuillier","year":"2022","unstructured":"Lhuillier M, Aoust L, Dreano E, Franco-Montoya ML, Landry-Truchon K, Houde N, et al. Elexacaftor\/tezacaftor\/ivacaftor disrupts respiratory tract development in a murine fetal lung explant model. Am J Respir Cell Mol Biol. 2022;67:723\u20136.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2594_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.therap.2022.01.020","volume":"77","author":"A Nuytten","year":"2022","unstructured":"Nuytten A, Prevotat A, Le Rouzic O, Dekemp J, Gilliot S, Gautier S, et al. Pulmonary hemorrhage in a neonate born to a woman with cystic fibrosis treated with targeted cystic fibrosis transmembrane conductance regulator modulator elexacaftor\u2013tezacaftor\u2013ivacaftor during pregnancy. Therapies. 2022;77:743\u20135.","journal-title":"Therapies"},{"key":"2594_CR44","doi-asserted-by":"crossref","unstructured":"Gautier S, Coulm B, Thompson-Bos MA, Chouchana L, Audousset C, Elefant E, et al. Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: a multicentre prospective case series. J Cyst Fibros. 2025;24:1051\u20137.","DOI":"10.1016\/j.jcf.2025.06.001"},{"key":"2594_CR45","doi-asserted-by":"publisher","first-page":"116155","DOI":"10.1016\/j.biopha.2024.116155","volume":"171","author":"D Li","year":"2024","unstructured":"Li D, Zhu Y, Donnelley M, Parsons D, Habgood MD, Schneider-Futschik EK. Fetal drug exposure after maternally administered CFTR modulators elexacaftor\/tezacaftor\/ivacaftor in a rat model. Biomed Pharmacother Biomed Pharmacother. 2024;171:116155.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"2594_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcf.2024.09.007","volume":"24","author":"JL Taylor-Cousar","year":"2025","unstructured":"Taylor-Cousar JL, Fakhari S, Allison L, Bartels DJ, Jain R, Han S. CF Ferrets exposed to in utero ivacaftor do not develop lens abnormalities. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2025;24:19\u201320.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR47","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","volume":"21","author":"R Jain","year":"2022","unstructured":"Jain R, Wolf A, Molad M, Taylor-Cousar J, Esther CR, Shteinberg M. Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21:1074\u20136.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","volume":"20","author":"JL Taylor-Cousar","year":"2021","unstructured":"Taylor-Cousar JL, Jain R. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20:402\u20136.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR49","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","volume":"19","author":"EF Nash","year":"2020","unstructured":"Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2020;19:521\u20136.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jcf.2025.03.009","volume":"24","author":"AS Bonnel","year":"2025","unstructured":"Bonnel AS, Bihou\u00e9e T, Ribault M, Driessen M, Gr\u00e8vent D, Foissac F, et al. First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: report from the MODUL-CF study. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2025;24:457\u201365.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jcf.2024.09.025","volume":"24","author":"TJ Kolaczkowski","year":"2025","unstructured":"Kolaczkowski TJ, Bevan A, Legg J, Self J, Allenby M. Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding \u2013 case reports. J Cyst Fibros. 2025;24:16\u20138.","journal-title":"J Cyst Fibros"},{"key":"2594_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","volume":"21","author":"B Collins","year":"2022","unstructured":"Collins B, Fortner C, Cotey A, Esther CR, Trimble A. Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21:725\u20137.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR53","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","volume":"24","author":"L Chouchana","year":"2025","unstructured":"Chouchana L, Collier M, Martin C, Burgel PR, Treluyer JM. CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study. J Cyst Fibros. 2025;24:469\u201375.","journal-title":"J Cyst Fibros"},{"key":"2594_CR54","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3109\/14767058.2016.1161747","volume":"30","author":"AC Jelin","year":"2017","unstructured":"Jelin AC, Sharshiner R, Caughey AB. Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis. J Matern-Fetal Neonatal Med. 2017;30:4\u20137.","journal-title":"J Matern-Fetal Neonatal Med"},{"key":"2594_CR55","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jcf.2020.08.003","volume":"20","author":"JL Taylor-Cousar","year":"2021","unstructured":"Taylor-Cousar JL, Jain R, Kazmerski TM, Aitken ML, West NE, Wilson A, et al. Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2021;20:395\u20136.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR56","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","volume":"17","author":"AT Trimble","year":"2018","unstructured":"Trimble AT, Donaldson SH. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2018;17:e13\u20136.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR57","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.suc.2022.07.016","volume":"102","author":"J Tobias","year":"2022","unstructured":"Tobias J, Tillotson M, Maloney L, Fialkowski E. Meconium ileus, distal intestinal obstruction syndrome, and other gastrointestinal pathology in the cystic fibrosis patient. Surg Clin North Am. 2022;102:873\u201382.","journal-title":"Surg Clin North Am"},{"key":"2594_CR58","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jcf.2019.10.003","volume":"18","author":"M Sathe","year":"2019","unstructured":"Sathe M, Houwen R. Is meconium ileus associated with worse outcomes in cystic fibrosis?. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2019;18:746.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR59","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jcf.2024.11.011","volume":"24","author":"A Metcalf","year":"2025","unstructured":"Metcalf A, Martiniano SL, Sagel SD, Zaretsky MV, Zemanick ET, Hoppe JE. Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2025;24:466\u20138.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR60","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","volume":"21","author":"S Szentpetery","year":"2022","unstructured":"Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, et al. A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2022;21:721\u20134.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR61","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.7326\/L23-0112","volume":"176","author":"YJ Blumenfeld","year":"2023","unstructured":"Blumenfeld YJ, Hintz SR, Aziz N, Barth RA, Spano JM, El-Sayed YY, et al. Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy. Ann Intern Med. 2023;176:1015\u20136.","journal-title":"Ann Intern Med"},{"key":"2594_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7531","volume":"11","author":"X Sun","year":"2019","unstructured":"Sun X, Yi Y, Yan Z, Rosen BH, Liang B, Winter MC, et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med. 2019;11:eaau7531.","journal-title":"Sci Transl Med"},{"key":"2594_CR63","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jcf.2024.06.003","volume":"23","author":"A Kowalik","year":"2024","unstructured":"Kowalik A, Roberts E, Harris AH, Sund M, Wird S, Kvist O, et al. Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnancies. J Cyst Fibros Off J Eur Cyst Fibros Soc. 2024;23:1027\u201330.","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"2594_CR64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","volume":"20","author":"CN Fortner","year":"2021","unstructured":"Fortner CN, Seguin JM, Kay DM. Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy. J Cyst Fibros. 2021;20:835\u20136.","journal-title":"J Cyst Fibros"},{"key":"2594_CR65","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","volume":"21","author":"S Szentpetery","year":"2022","unstructured":"Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, et al. A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. J Cyst Fibros. 2022;21:721\u20134.","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02594-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02594-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02594-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:03:11Z","timestamp":1785463391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02594-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2594"],"URL":"https:\/\/doi.org\/10.1038\/s41372-026-02594-0","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}